Thymosin Alpha-1: What It Changed and What It Didn't
This 28-amino-acid protein has small linked parts called amino acids. You'll see where people improved and where the drug failed.
What the protein may do in your body
A small protein called Thymosin Alpha-1 comes from your body. This page covers where studies found help and where they didn't. The protein has 28 small parts called amino acids. Your thymus sits high in the chest and helps train immune cells.
Muscle growth isn't one of this protein's roles. A matching drug made in a lab is called thymalfasin. Doctors abroad use it for long-term hepatitis, a liver illness, and weak immune defenses. It's approved in about 35 countries, but not for US sale.
Here's the catch for you. The steadiest results come from long-term liver illness. The biggest sepsis study didn't save more lives during that grave infection. The effects page keeps personal reports apart from study results.
What Thymosin Alpha-1 changed across four decades
Early Thymosin Alpha-1 work used protein taken from a calf gland, but no sick person received it there, so the work couldn't show whether anyone improved during that first lab work. In 1977, Allan Goldstein's team listed the 28-amino-acid chain; its amino acids are tiny linked protein parts [1]. That list let other labs make the same protein.
The next tests kept living cells in dishes. The protein helped lookout cells call in T-cells, immune cells that hunt infected cells [5]. It also started a calming step that might keep the fight from going too far [5]. What cells do in a dish can't tell you whether your illness will ease.
Results in people are mixed. Studies cover liver illness, sepsis, COVID-19, and cancer care [4]. A broad review says more than 35 countries approve the drug, and soreness near the needle is the usual complaint [4]. The Thymosin Alpha-1 research page puts each result beside its limits.
What helped people and what failed
Start with the limit. Results changed with the illness being treated. The steadiest help appeared in long-term viral hepatitis. A broad review found mostly mild trouble near the needle spot [4].
Sepsis brought the harder answer. An early study of 361 people found 28-day death rates of 26.0% with the drug and 35.0% without it, about a 9-point gap at the end of the first month [2]. The larger phase-3 test in 2025 was built as a late, firm check of benefit. It followed 1,106 adults, but rates of 23.4% and 24.1% were too close to show help [3].
The COVID-19 result is less sure because it came from old charts. Among 76 very sick people, death rates were 11.11% with treatment and 30.00% without it [6]. Blood tests also found more T-cells, the immune cells that hunt infected cells. The charts can't show that the medicine caused either change for you.
What the site can tell you and what it can't
This site reads Thymosin Alpha-1 studies and tells you what happened. No clinic runs it, and nothing is sold here. Any shown amount came from a study; it wasn't picked for you. Your doctor still needs your full health record.
You can check Thymosin Alpha-1 effects, read the research, or open the Thymosin Alpha-1 references. The names need care. Thymosin beta-4 (TB-500) helps cells move, while thymulin, thymopentin, and thymalin are other substances made in or from the thymus. Prothymosin alpha is the larger protein your body cuts, and Thymosin Alpha-1 itself has a different name and role on the thymosin alpha 1 peptide page when you read a label.